Previous 10 | Next 10 |
BiondVax (NASDAQ: BVXV) , a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals...
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai ”). In the past two years, the Company ...
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...
A group of infectious disease experts from several American Army institutions has been deployed to analyze mosquitoes after Maryland recently confirmed its first nontravel-connected malaria case in more than 40 years. Experts from the Walter Reed Army Institute of Research (WRAIR), the Smithson...
A leading national patient United Kingdom charity is concerned with the “hugely worrying” rise of allergy-related hospitalizations in England. Dangerous allergic reactions in the UK have risen in recent years and now average around 25,000 NHS hospital stays every year. According t...
BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designe...
The Centers for Disease Control and Prevention (CDC) estimates that close to one in three adults and more than one in every four children in America have a food allergy, seasonal allergy or eczema. Close to 6% of children and adults in the country have a food allergy and 25.7% of U.S. adults ha...
Autoimmune diseases occur when the immune system mistakes healthy tissues for harmful bacteria, viruses, or infections and starts to attack the body. Referred to as autoimmunity , this phenomenon causes significant damage to healthy tissues and results in more than 100 autoimmune conditions. ...
Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better bin...
BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis ti...
News, Short Squeeze, Breakout and More Instantly...
BiondVax Pharmaceuticals Ltd. Company Name:
BVXV Stock Symbol:
NASDAQ Market:
BiondVax (NASDAQ: BVXV) , a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals...
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai ”). In the past two years, the Company ...
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...